Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer

Annals of Oncology

Volumn 25, Issue 6, 2014, Pages 1158-1164

  Han, X ^a   Diao, L ^a   Xu, Y ^a   Xue, W ^b   Ouyang, T ^a   Li, J ^a   Wang, T ^a   Fan, Z ^a   Fan, T ^a   Lin, B ^a   Xie, Yuntao ^a  

^a China   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Breast cancer; HER2 gene; Polymorphism; Response; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ISOLEUCINE; PROGESTERONE RECEPTOR; TRASTUZUMAB; VALINE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HER2 GENE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; AGED; BREAST NEOPLASMS; DRUG RESISTANCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROTO ONCOGENE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2;

EID: 84903907924     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu111     Document Type: Article

References (21)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
2. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
3. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
4. Carter P, Presta L, Gorman CM et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-4289.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
6. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
7. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
8. Gianni L, Dafni U, Gelber RD et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12: 236-244.
9. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283.
10. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
11. Nielsen DL, Kumler I, Palshof JA et al. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 2013; 22: 1-12.
12. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
13. Papewalis J, Nikitin A, Rajewsky MF. G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res 1991; 19: 5452.
14. Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 2002; 99: 15937-15940.
15. Takano K, Ogasahara K, Kaneda H et al. Contribution of hydrophobic residues to the stability of human lysozyme: calorimetric studies and X-ray structural analysis of the five isoleucine to valine mutants. J Mol Biol 1995; 254: 62-76.
16. Xie D, Shu XO, Deng Z et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000; 92: 412-417.
17. Tao W, Wang C, Han R et al. HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2009; 114: 371-376.
18. Ma Y, Yang J, Zhang P et al. Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects. Breast Cancer Res Treat 2011; 125: 237-241.
19. Tsutsui S, Ohno S, Murakami S et al. Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol 2002; 79: 216-223.
20. Musolino A, Ciccolallo L, Panebianco M et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 2011; 117: 1837-1846.
21. Beauclair S, Formento P, Fischel JL et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol 2007; 18: 1335-1341.